Fatty Livers is a condition that is becoming very common, and Endonovo is the Only biotech currently developing a non-invasive, non-pharmacological approach for the treatment of NASH, an inflammatory condition in the liver due to a buildup of fat that can lead to cirrhosis and liver failure if left untreated that can lead to liver failure.
If this study, or any of the other studies that are currently in process are completed this a high degree of success, we are in for one exciting ride. Consider the following:
This traded at .70 18 months ago w/ no trial results. It ran to .14 earlier this year....again w/ no news. I think a dollar or more is a conservative forecast w/ positive trial results. However, you have to keep in mind that once they prove the technology works on one trial, the likelihood that it works for many ailments is extremely probable. That being said a multiple dollars plus is definitely a possibility.
Don't be surprised if after the release of just one successful study we login to our trading account and find ENDV trading for $3.50 a share. It's happened to other stocks and it could happen here.
If this study, or any of the other studies that are currently in process are completed this a high degree of success, we are in for one exciting ride. Consider the following:
This traded at .70 18 months ago w/ no trial results. It ran to .14 earlier this year....again w/ no news. I think a dollar or more is a conservative forecast w/ positive trial results. However, you have to keep in mind that once they prove the technology works on one trial, the likelihood that it works for many ailments is extremely probable. That being said a multiple dollars plus is definitely a possibility.
Don't be surprised if after the release of just one successful study we login to our trading account and find ENDV trading for $3.50 a share. It's happened to other stocks and it could happen here.
